PharmaResearch is accelerating its non-aesthetic portfolio expansion with Conjuran, a polynucleotide (PN)-based intra-articular injection device for knee joints. The company recently launched a short video ad on its official YouTube channel, using the catchy slogan "For knees? Sook~ Conjuran" to build brand recognition. This move extends PharmaResearch's aesthetic brand communication expertise into the orthopedic market, signaling a strategic diversification for overseas buyers and distributors watching the medical aesthetics supply chain.
Product and technology foundation
Conjuran is a PN-based intra-articular medical device applying PharmaResearch's DOT® technology. According to official product information, it is injected into the joint cavity to physically restore the area and reduce mechanical friction. The device has received approval from South Korea's Ministry of Food and Drug Safety (MFDS), and its injection technology using polynucleotide sodium is registered as a new medical technology in the country. This clear regulatory and technical basis underpins Conjuran's steady market attention.
Clinical evidence and academic engagement
PharmaResearch has built clinical credibility through symposiums and academic exchanges with musculoskeletal medical professionals. Domestic clinical results and real-world application cases have been shared at these events. A large-scale MOST 1,050-patient trial confirmed sustained pain reduction at six months, with an adverse event rate of only 0.55%. This combination of market communication and academic activity enhances product trust among clinicians and potential buyers.
International expansion signals
Conjuran's overseas potential is a key watchpoint. PharmaResearch recently obtained product approval from Malaysia's Medical Device Authority (MDA), establishing a base for Southeast Asian market entry. The company views Malaysia as a high-growth market and plans to leverage its DOT® PN technology to meet local demand. While Rejuran has built global experience in aesthetics, Conjuran demonstrates PharmaResearch's technology platform scalability in the joint injection segment.
Regulatory and channel signals
A court has granted a stay of execution regarding restrictions on Conjuran re-administration, suspending the administrative effect of the relevant reimbursement notice until a final ruling. PharmaResearch stated it aims to minimize patient inconvenience and market disruption. Industry observers see this as an effort to secure product sustainability within the clinical and regulatory environment, beyond mere sales.
Sourcing context
PharmaResearch is also advancing its pipeline with NPNP-001, a next-generation PN knee joint injection, which has entered confirmatory clinical trials. This indicates Conjuran is managed as a mid-to-long-term strategic product line, not a one-off item. For overseas importers and distributors, the combination of approved technology, clinical data, regulatory navigation, and pipeline development makes Conjuran a noteworthy product for portfolio diversification in non-aesthetic medical devices.
Source: Read the original report | Published: June 02, 2026